WATCH LIVE
timothy sykes logo
ALXO Stock Edges Higher As Jefferies Conference Spotlights Oncology Pipeline Thumbnail
G Google News

ALXO Stock Edges Higher As Jefferies Conference Spotlights Oncology Pipeline

MATT MONACO•UPDATED JUN. 28, 2026, 10:08 AM ET
Reviewed by Jack Kelloggand Fact-checked by Tim Sykes

ALX Oncology Holdings Inc. soared as breakthrough clinical news fueled optimism, and stocks have been trading up by 11.73 percent.

What Traders Need To Know

  • Participation in the 2026 Jefferies Global Healthcare Conference puts ALX Oncology Holdings Inc. in front of a high-profile healthcare audience, with webcast access expanding reach.
  • Management will spotlight the clinical-stage pipeline, which is the core value driver for ALXO at this early stage.
  • Focus of the fireside chat will be lead CD47 blocker evorpacept and EGFR-targeted ADC ALX2004, two key assets that can fuel speculation around trial updates and future catalysts.
  • Recent price action shows ALXO pushing off weekly lows toward $2, hinting at growing interest ahead of the conference appearance.

Candlestick Chart

Weekly Update Jun 22 – Jun 26, 2026: On Sunday, June 28, 2026 ALX Oncology Holdings Inc. stock [NASDAQ: ALXO] is trending up by 11.73%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

ALX Oncology (ALXO) remains an early‑stage, pre‑revenue biotech with a balance sheet that provides a limited but real runway. Q1 2026 operating cash burn was about $18.6 million, with free cash flow of -$18.7 million, offset by $139.6 million in financing inflows, driving cash and short-term investments to roughly $140 million and a current ratio of 7.2. Returns on assets and equity are deeply negative, consistent with a clinical platform company, while leverage is modest with debt‑to‑equity at 0.06.

Technically, ALXO has shifted from a flat base at $1.63 to a sharp upside move, closing the latest session at $2.00 after hitting $2.10 intraday. The weekly pattern shows higher lows and higher highs, signaling a nascent uptrend likely driven by event speculation and elevated volume versus prior days. Dominant resistance sits at $2.10; a decisive break above on strong volume offers a tactical long entry, with $1.70–1.75 as near‑term support and a logical stop region.

The Jefferies Global Healthcare Conference appearance underscores ALXO’s effort to reposition investor focus on evorpacept and the ALX2004 ADC platform, key differentiators versus broader Healthcare and Biotechnology & Life Sciences benchmarks increasingly favoring late‑stage or commercial names. Given its cash, pipeline optionality, and early trend reversal, the outlook is cautiously constructive. I see a 3–6 month trading band of $1.70–2.75, with interim resistance at $2.50 and structural support at $1.50; risk remains high but asymmetry is improving.

More Breaking News

Quick Financial Overview

ALX Oncology Holdings Inc. is behaving like a classic clinical-stage biotech on the chart and in the numbers. Weekly data show the stock grinding higher from $1.63 to around $2 into late 2026/06/26, with higher lows and a mild expansion in the weekly range. That type of climb, while still low-priced, often signals early positioning by traders ahead of potential news or visibility events, such as the upcoming Jefferies fireside chat.

On the intraday side, a single 5-minute snapshot shows a wide candle from roughly $1.79 to $2.13 before settling near $2.04. That kind of intraday rip, with a strong close off the lows, suggests aggressive dip buying and short-term momentum interest. For a thin clinical name like ALXO, traders should assume moves can be sharp both ways when liquidity thins out.

Fundamentally, ALX Oncology remains loss-making, with Q1 2026 net income at about -$17.9M and operating cash flow around -$18.6M. However, the balance sheet shows roughly $140.3M in cash and short-term investments, a current ratio above 7, and very low debt (total debt-to-equity near 0.06). Price-to-book around 1.5 and deeply negative return metrics underscore a typical high-burn, pre-revenue setup where pipeline progress — not current earnings — drives value. For traders, that means news flow around evorpacept and ALX2004 is far more important than traditional valuation ratios.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”